News Lilly, PTC snap up bankrupt Sangamo's main assets Just a few weeks after filing for bankruptcy protection, Sangamo has found buyers for some of its key assets, raising up to $263.5m.
News Lilly sues over 'illegal sales' of obesity drug retatrutide Eli Lilly has sued six US-based companies it accuses of participating in an illegal black market for experimental weight-loss drug retatrutide.
News UK is first European country to approve Lilly's Foundayo Eli Lilly's oral GLP-1 agonist Foundayo has been approved for weight management and type 2 diabetes in the UK, its first European market.
News Lilly's GLP-1s race away in Q2, though Foundayo falls short Eli Lilly has posted another record quarter of revenue growth, up 48% to $23bn, with Mounjaro and Zepbound now making up two-thirds of the total.
News Lilly plans Q1 2027 filing for obesity triple retatrutide Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.
News Novo sues Lilly over 'misleading' GLP-1 ad campaigning The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.
News After failure in sickle cell, Fulcrum merges with Slate Following the failure of its sickle cell programme, Fulcrum Therapeutics will merge with Slate Medicines to advance Slate's migraine therapy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
